Bristol-Myers Has $11 Million Antitrust Deal on Gilead HIV Drugs

Bristol-Myers Squibb Co. will pay up to $11 million to exit antitrust litigation over claims it helped delay generic versions of Gilead Sciences Inc.'s blockbuster HIV drugs, bringing its total settlement amount to roughly $21 million, according to a federal court filing in San Francisco.

The drug distributors leading part of the case sought preliminary approval Wednesday for the agreement, which would resolve class action claims filed in the U.S. District Court for the Northern District of California on behalf of direct purchasers of Truvada and other HIV medications in the same family.

The deal—which includes $10.8 million in damages ...